

# An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16)

**First published:** 25/08/2023

**Last updated:** 15/07/2024

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS106401

---

### Study ID

106402

---

### DARWIN EU® study

No

---

### Study countries

- ☐ Brazil
  - ☐ Germany
  - ☐ Italy
  - ☐ Spain
  - ☐ United Kingdom
- 

### Study description

This prospective, international, longitudinal cohort study will evaluate the effectiveness and safety of elranatamab in routine clinical practice in patients 18 years and older. Approximately 198 patients will be recruited from primary care centers, hematology/oncology clinics, and academic centers in the Germany, the United Kingdom, Brazil, Spain and Italy. Each patient's treatment will be consistent with routine practice, at the discretion of the treating physician and according to the local Health Authority approved product label. After Health Authority approval, multiple myeloma patients receiving at least one dose of elranatamab who satisfy the inclusion and exclusion criteria may be enrolled. Patients will be followed prospectively for up to 3 years after enrollment in the study or until withdrawal, physician discretion, loss to follow-up, death, or study termination, whichever occurs the earliest.

---

### Study status

Ongoing

## Research institutions and networks

### Institutions

Pfizer

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

**IQVIA**

☐ United Kingdom

**First published:** 12/11/2021

**Last updated:** 22/04/2024

**Institution**

**Non-Pharmaceutical company**

**ENCePP partner**

**iOMEDICO**

☐ Germany

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

**Non-Pharmaceutical company**

## Contact details

### Study institution contact

Rebecca Levin rebecca.levin@pfizer.com

**Study contact**

[rebecca.levin@pfizer.com](mailto:rebecca.levin@pfizer.com)

## Primary lead investigator

Rebecca Levin

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 04/04/2023

Actual: 27/07/2023

---

### Study start date

Planned: 01/11/2023

Actual: 09/07/2024

---

### Data analysis start date

Planned: 30/08/2029

---

### Date of final study report

Planned: 24/11/2029

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Pfizer

# Study protocol

[C1071016\\_Protocol\\_Elranatamab NIS\\_V1.0\\_31Aug2023\\_FINAL\\_redacted.pdf](#)  
(800.55 KB)

[C1071016\\_Protocol\\_Elranatamab  
NIS\\_V2.0\\_04Jun2024\\_FINAL\\_Signed\\_Redacted.pdf](#)(950.05 KB)

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Human medicinal product

---

**Study topic, other:**

Real World Safety and Effectiveness

**Study type:**

Non-interventional study

---

**Scope of the study:**

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

**Study design:**

This prospective, international, longitudinal cohort study will follow patients for up to 3 years or until withdrawal, physician discretion (i.e., patient health), loss to follow up, death, or study termination. Effectiveness outcomes and adverse events will be evaluated descriptively.

**Main study objective:**

To evaluate the effectiveness of elranatamab through the collection and analysis of the following clinical outcomes (defined according to the IMWG consensus criteria for response and minimal residual disease assessment in MM): Overall response rate (ORR), Time to response (TTR), Duration of response (DOR), Progression free survival (PFS), Overall survival (OS), Time to next treatment (TTNT).

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Name of medicine**

ELREXFIO

---

**Name of medicine, other**

Elranatamab

---

**Medical condition to be studied**

Plasma cell myeloma refractory

## Population studied

**Short description of the study population**

Male or female patients, age  $\geq 18$  years, with RRMM who are newly treated with elranatamab according to the local Health Authority approved product label (routine-care).

---

**Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

**Estimated number of subjects**

198

## Study design details

## **Setting**

Patients will be recruited from primary care centers, hematology/oncology clinics, and academic treatment centers to ensure broad physician and patient representation. Recruitment of sites will begin with invitations to hematologists/oncologists who are most likely to treat patients with RRMM and will continue until the target number of patients has been met or 2 years after the first patient is enrolled. Approximately 198 patients will be recruited from primary care centers, hematology/oncology clinics, and academic centers from Germany, the United Kingdom, Brazil, Italy and Spain. Study will aim to enroll patients with a diverse distribution of characteristics (e.g., race, ethnicity, sex) that is representative of the real-world patient population being treated with elranatamab in clinical practice. Thus, both urban/university hospitals and rural community centers are included in this study.

---

## **Outcomes**

Effectiveness outcomes include ORR, TTR, DOR, PFS, and OS according to the IMWG consensus criteria for response in MM. TTNT will be defined as the time from elranatamab initiation to next treatment. Safety event will be collected, reported and summarized by the enrolling physician or other treatment team member for up to 90 days after the last dose of elranatamab.

---

## **Data analysis plan**

The characteristics captured during baseline and follow up will be summarized using descriptive statistics. Frequencies and percentages will be used for categorical variables and mean (standard deviation STD) and median (interquartile range IQR) will be used for continuous variables. For the effectiveness outcomes of interest, ORR will be summarized using frequencies and percentages and time-to-event outcomes (DOR, TTR, PFS, OS, TTNT) will be evaluated using Kaplan-Meier (KM) methods. KM curves will be illustrated and the median survival and corresponding 95% confidence interval (95% CI) will be



computed. To evaluate the safety of elranatamab, AEs and SAEs will be collected on a structured data collection tool Adverse Event Monitoring (AEM) form and will be characterized by type, grade, timing, seriousness, and relationship to elranatamab. Crude cumulative incidence will be calculated as appropriate.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

[Other](#)

---

### Data sources (types), other

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No